<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/562"/><api:result><api:object category="publication" id="562" last-affected-when="2024-03-25T13:22:55.43+00:00" last-modified-when="2024-03-25T13:22:55.43+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/562" created-when="2010-05-17T13:46:23.013+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:merge-history><api:merge when="2016-12-22T09:01:50.427+00:00"><api:merged-object id="22492" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/deleted/publications/22492"/><api:merged-into-object id="562" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/562"/></api:merge></api:merge-history><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-10-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1356832" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.2337/diacare.22.10.1607" last-modified-when="2022-09-12T01:36:35.07+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;jats:p&gt;OBJECTIVE: To measure the effectiveness of insulin lispro, a fast-acting insulin analog, in reducing hypoglycemic episodes when used in a basal bolus regimen by patients with type 1 diabetes using intensive insulin therapy. RESEARCH DESIGN AND METHODS: In 11 diabetes outpatient clinics in the U.K., 165 subjects with type 1 diabetes were enrolled in a randomized crossover open-label study with a 2-month run-in period and then treated with a basal bolus regimen. Patients used human NPH insulin at night with either premeal insulin lispro for 4 months followed by human regular insulin for another 4 months or human regular insulin for 4 months followed by insulin lispro for another 4 months. The main outcome measures were the number of hypoglycemic episodes during both treatments and HbA1c level. RESULTS: A total of 135 patients were randomized, with 68 receiving insulin lispro and 67 receiving human regular insulin for the first 4 months. The data for the first 4 months of treatment only were compared as two independent groups because of a period effect and a treatment-period interaction. Glycemic control was equally tight during treatment with human regular insulin (HbA1c, 6.2 +/- 0.8%) and insulin lispro (6.0 +/- 0.9%). A total of 1,156 hypoglycemic episodes occurred during treatment with human regular insulin compared with 775 hypoglycemic episodes that occurred during treatment with insulin lispro (P = 0.04). This difference was chiefly because of a reduced number of nocturnal episodes (181 vs. 52, P = 0.001) in the insulin lispro group. CONCLUSIONS: The use of a fast-acting insulin analog, insulin lispro, as part of a basal bolus regimen reduces nocturnal hypoglycemia in patients with type 1 diabetes who maintain tight glycemic control during intensive insulin therapy.&lt;/jats:p&gt;</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1935-5548</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Diabetes Care</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>American Diabetes Association</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.2337/diacare.22.10.1607</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>12</api:day><api:month>3</api:month><api:year>2022</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="94561" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0032861268" last-modified-when="2023-05-10T04:21:49.6+01:00"><api:citation-count>154</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>OBJECTIVE: To measure the effectiveness of insulin lispro, a fast-acting insulin analog, in reducing hypoglycemic episodes when used in a basal bolus regimen by patients with type 1 diabetes using intensive insulin therapy. RESEARCH DESIGN AND METHODS: In 11 diabetes outpatient clinics in the U.K., 165 subjects with type 1 diabetes were enrolled in a randomized crossover open-label study with a 2-month run-in period and then treated with a basal bolus regimen. Patients used human NPH insulin at night with either premeal insulin lispro for 4 months followed by human regular insulin for another 4 months or human regular insulin for 4 months followed by insulin lispro for another 4 months. The main outcome measures were the number of hypoglycemic episodes during both treatments and HbA(1c) level. RESULTS: A total of 135 patients were randomized, with 68 receiving insulin lispro and 67 receiving human regular insulin for the first 4 months. The data for the first 4 months of treatment only were compared as two independent groups because of a period effect and a treatment-period interaction. Glycemic control was equally tight during treatment with human regular insulin (HbA(1c), 6.2 ±0.8%) and insulin lispro (6.0 ±0.9%). A total of 1,156 hypoglycemic episodes occurred during treatment with human regular insulin compared with 775 hypoglycemic episodes that occurred during treatment with insulin lispro (P = 0.04). This difference was chiefly because of a reduced number of nocturnal episodes (181 vs. 52, P = 0.001) in the insulin lispro group. CONCLUSIONS: The use of a fast-acting insulin analog, insulin lispro, as part of a basal bolus regimen reduces nocturnal hypoglycemia in patients with type 1 diabetes who maintain tight glycemic control during intensive insulin therapy.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Northern General Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="GB"><api:line type="organisation">The University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7101979372</api:identifier></api:identifiers></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">King's College London</api:line><api:line type="city">London</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005763485</api:identifier></api:identifiers></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Salisbury District Hospital</api:line><api:line type="city">Salisbury</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004498849</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10526722</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Diabetes Care</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="562" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10526722" last-modified-when="2022-12-20T21:02:25.963+00:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>OBJECTIVE: To measure the effectiveness of insulin lispro, a fast-acting insulin analog, in reducing hypoglycemic episodes when used in a basal bolus regimen by patients with type 1 diabetes using intensive insulin therapy. RESEARCH DESIGN AND METHODS: In 11 diabetes outpatient clinics in the U.K., 165 subjects with type 1 diabetes were enrolled in a randomized crossover open-label study with a 2-month run-in period and then treated with a basal bolus regimen. Patients used human NPH insulin at night with either premeal insulin lispro for 4 months followed by human regular insulin for another 4 months or human regular insulin for 4 months followed by insulin lispro for another 4 months. The main outcome measures were the number of hypoglycemic episodes during both treatments and HbA1c level. RESULTS: A total of 135 patients were randomized, with 68 receiving insulin lispro and 67 receiving human regular insulin for the first 4 months. The data for the first 4 months of treatment only were compared as two independent groups because of a period effect and a treatment-period interaction. Glycemic control was equally tight during treatment with human regular insulin (HbA1c, 6.2 +/- 0.8%) and insulin lispro (6.0 +/- 0.9%). A total of 1,156 hypoglycemic episodes occurred during treatment with human regular insulin compared with 775 hypoglycemic episodes that occurred during treatment with insulin lispro (P = 0.04). This difference was chiefly because of a reduced number of nocturnal episodes (181 vs. 52, P = 0.001) in the insulin lispro group. CONCLUSIONS: The use of a fast-acting insulin analog, insulin lispro, as part of a basal bolus regimen reduces nocturnal hypoglycemia in patients with type 1 diabetes who maintain tight glycemic control during intensive insulin therapy.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Northern General Hospital, Sheffield, U.K. s.heller@sheffield.ac.uk</api:line></api:address></api:addresses><api:email-address>s.heller@sheffield.ac.uk</api:email-address></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10526722</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Diabetes Care</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Blood Glucose</api:keyword><api:keyword scheme="mesh">Circadian Rhythm</api:keyword><api:keyword scheme="mesh">Cross-Over Studies</api:keyword><api:keyword scheme="mesh">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Glycated Hemoglobin</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hypoglycemia</api:keyword><api:keyword scheme="mesh">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh">Insulin</api:keyword><api:keyword scheme="mesh">Insulin Lispro</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Risk Factors</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>United States</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>16</api:day><api:month>11</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Comparative Study</api:item><api:item>Journal Article</api:item><api:item>Multicenter Study</api:item><api:item>Randomized Controlled Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="881917" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10526722" last-modified-when="2023-01-31T17:46:06.443+00:00"><api:citation-count>82</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Objective&lt;/h4&gt;To measure the effectiveness of insulin lispro, a fast-acting insulin analog, in reducing hypoglycemic episodes when used in a basal bolus regimen by patients with type 1 diabetes using intensive insulin therapy.&lt;h4&gt;Research design and methods&lt;/h4&gt;In 11 diabetes outpatient clinics in the U.K., 165 subjects with type 1 diabetes were enrolled in a randomized crossover open-label study with a 2-month run-in period and then treated with a basal bolus regimen. Patients used human NPH insulin at night with either premeal insulin lispro for 4 months followed by human regular insulin for another 4 months or human regular insulin for 4 months followed by insulin lispro for another 4 months. The main outcome measures were the number of hypoglycemic episodes during both treatments and HbA1c level.&lt;h4&gt;Results&lt;/h4&gt;A total of 135 patients were randomized, with 68 receiving insulin lispro and 67 receiving human regular insulin for the first 4 months. The data for the first 4 months of treatment only were compared as two independent groups because of a period effect and a treatment-period interaction. Glycemic control was equally tight during treatment with human regular insulin (HbA1c, 6.2 +/- 0.8%) and insulin lispro (6.0 +/- 0.9%). A total of 1,156 hypoglycemic episodes occurred during treatment with human regular insulin compared with 775 hypoglycemic episodes that occurred during treatment with insulin lispro (P = 0.04). This difference was chiefly because of a reduced number of nocturnal episodes (181 vs. 52, P = 0.001) in the insulin lispro group.&lt;h4&gt;Conclusions&lt;/h4&gt;The use of a fast-acting insulin analog, insulin lispro, as part of a basal bolus regimen reduces nocturnal hypoglycemia in patients with type 1 diabetes who maintain tight glycemic control during intensive insulin therapy.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Northern General Hospital, Sheffield, U.K. s.heller@sheffield.ac.uk</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-2425-9565</api:identifier></api:identifiers></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1935-5548</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10526722</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Diabetes care</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh">Hypoglycemia</api:keyword><api:keyword scheme="mesh">Insulin</api:keyword><api:keyword scheme="mesh">Blood Glucose</api:keyword><api:keyword scheme="mesh">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh">Risk Factors</api:keyword><api:keyword scheme="mesh">Cross-Over Studies</api:keyword><api:keyword scheme="mesh">Circadian Rhythm</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Insulin Lispro</api:keyword><api:keyword scheme="mesh">Glycated Hemoglobin</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>20</api:day><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Clinical Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Multicenter Study</api:item><api:item>Randomized Controlled Trial</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="2932122" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1070748494" last-modified-when="2024-03-17T09:33:04.03+00:00"><api:citation-count>131</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>6</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Northern General Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0670713710.03</api:identifier></api:identifiers></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Northern General Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014251000701.41</api:identifier></api:identifiers></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Northern General Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0734742375.55</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10526722</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>1066-9442</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/999164"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Diabetes Care</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Autoimmune Disease</api:keyword><api:keyword scheme="rcdc">Diabetes</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Prevention</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Metabolic and endocrine</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Blood Glucose</api:keyword><api:keyword scheme="mesh">Circadian Rhythm</api:keyword><api:keyword scheme="mesh">Cross-Over Studies</api:keyword><api:keyword scheme="mesh">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Glycated Hemoglobin</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hypoglycemia</api:keyword><api:keyword scheme="mesh">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh">Insulin</api:keyword><api:keyword scheme="mesh">Insulin Lispro</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Risk Factors</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>American Diabetes Association</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>3.27</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="240672" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000082812700002" last-modified-when="2024-03-14T05:53:22.713+00:00"><api:citation-count>107</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000082812700002&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.2337/diacare.22.10.1607</api:text><api:links><api:link type="doi" href="http://doi.org/10.2337/diacare.22.10.1607"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.2337/diacare.22.10.1607"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1935-5548</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">240EJ</api:identifier><api:identifier scheme="pubmed">10526722</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>DIABETES CARE</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record><api:record format="native" id="23429" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000082812700002" last-modified-when="2016-12-22T09:01:50.43+00:00"><api:citation-count>81</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2048" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2048"/></api:links><api:last-name>Heller</api:last-name><api:initials>SR</api:initials><api:first-names>SR</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Amiel</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mansell</api:last-name><api:initials>P</api:initials><api:first-names>P</api:first-names><api:separate-first-names><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>UK Lispro Study Grp</api:last-name><api:initials></api:initials></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0149-5992</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>10</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>DIABETES CARE</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>IDDM PATIENTS</api:keyword><api:keyword>GLYCEMIC THRESHOLDS</api:keyword><api:keyword>PHARMACOKINETICS</api:keyword><api:keyword>FREQUENCY</api:keyword><api:keyword>LYS(B28),PRO(B29)</api:keyword><api:keyword>NEUROENDOCRINE</api:keyword><api:keyword>RESPONSES</api:keyword><api:keyword>MEAL</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1607</api:begin-page><api:end-page>1611</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>10</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>22</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Blood Glucose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Circadian Rhythm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cross-Over Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Glycated Hemoglobin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hypoglycemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Insulin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Insulin Lispro</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Risk Factors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hypoglycemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Insulin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Blood Glucose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Risk Factors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cross-Over Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Circadian Rhythm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Insulin Lispro</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Glycated Hemoglobin</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Autoimmune Disease</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Diabetes</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Prevention</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Metabolic and endocrine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Blood Glucose</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Circadian Rhythm</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cross-Over Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Diabetes Mellitus, Type 1</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Diabetic Neuropathies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Diabetic Retinopathy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Glycated Hemoglobin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hypoglycemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hypoglycemic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Insulin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Insulin Lispro</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Risk Factors</api:keyword><api:keyword origin="record-data" source="wos">IDDM PATIENTS</api:keyword><api:keyword origin="record-data" source="wos">GLYCEMIC THRESHOLDS</api:keyword><api:keyword origin="record-data" source="wos">PHARMACOKINETICS</api:keyword><api:keyword origin="record-data" source="wos">FREQUENCY</api:keyword><api:keyword origin="record-data" source="wos">LYS(B28),PRO(B29)</api:keyword><api:keyword origin="record-data" source="wos">NEUROENDOCRINE</api:keyword><api:keyword origin="record-data" source="wos">RESPONSES</api:keyword><api:keyword origin="record-data" source="wos">MEAL</api:keyword><api:keyword scheme="for" origin="issn-inferred">11 Medical and Health Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Endocrinology &amp; Metabolism</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">32 Biomedical and clinical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">42 Health sciences</api:keyword></api:keywords></api:all-labels><api:journal issn="0149-5992" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973810" title="Diabetes Care"><api:records><api:record source-name="summary"><api:title>Diabetes Care</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/562/relationships"/></api:object></api:result></api:response>